Adlai Nortye Group Ltd. appointed Christopher Liu, PharmD, as Head of Investor Relations and Public Relations on September 30, 2026. Dr. Liu joins the company with nearly a decade of equity research experience in biotechnology and oncology, most recently serving as Managing Director at Lucid Capital Markets. This appointment aims to strengthen engagement with the global investment community and enhance external communications regarding the company's clinical-stage pipeline. Adlai Nortye Group Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies.
